A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck using study drug MEDI4736
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAO5153
U.S. Govt. ID: NCT02319044
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck who have progressed during or after treatment with platinum-containing regimen for recurrent or metastatic disease.
This study is closed
Sewanti Limaye, MD
Do You Qualify?
Do you have at least one lesion? Yes No
Have you had prior exposure to immune-mediated therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton